✦ LIBER ✦

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

✍ Scribed by Alan K. Burnett; Nigel H. Russell; Dominic Culligan; Jamie Cavanagh; Jonathan Kell; Keith Wheatley; Andra Virchis; Robert K. Hills; Donald Milligan; on behalf of the AML Working Group of the UK National Cancer Research Institute

Book ID: 114714741
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 65 KB
Volume: 158
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2012.09165.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The addition of arsenic trioxide to low-

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome

✍ Burnett, A K; Hills, R K; Hunter, A; Milligan, D; Kell, J; Wheatley, K; Yin, J; 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 297 KB

510 Addition of All-Trans Retinoic Acid

510 Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, With or Without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation

✍ Asifa Malik; Carlos Bueso-Ramos; Stefan Faderl; Eli Estey; Susan O'Brien; Michae 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 153 KB

Does the Addition of Involved Field Radi

Does the Addition of Involved Field Radiotherapy to High-dose Chemotherapy and Stem Cell Transplantation Improve Outcomes for Patients with Relapsed/Refractory Hodgkin Lymphoma?

✍ Kahn, S.T.; Flowers, C.; Xu, Z.; Esiashvili, N. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 41 KB